Co-founded by Truffle Capital in 2008 with AirBus Group and Pr. Alain Carpentier, Carmat is a commercial-stage MedTech company developing a total artifical heart for patients with advanced biventricular heart failure. By eliminating the reliance on donor organs, Carmat seeks to enhance patient access and alleviate the burden of terminal heart failure.